New combo therapy shows promise for Steroid-Resistant ITP
NCT ID NCT05438875
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed phase 3 trial tested whether adding all-trans retinoic acid (ATRA) to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) that did not respond to steroids. The study enrolled 96 participants and measured sustained platelet count improvement at 18 months. The goal is to find a more effective treatment option for this chronic bleeding disorder.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
all-trans retinoic acid (ATRA) and eltrombopag
What this could lead to
If successful, this combination could offer a more effective treatment option for people with immune thrombocytopenia (ITP) that does not respond to steroids, helping maintain safe platelet levels.
What could go wrong
This is a relatively small phase 3 trial (96 participants), and results may not apply to all ITP patients. The combination may cause side effects, and long-term benefits are not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren hospital
Beijing, Beijing Municipality, China
-
Department of Hematology, Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Department of Hematology, Beijing Hospital
Beijing, China
-
Department of Hematology, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital
Beijing, China
-
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China